Many details of these agreements remain undisclosed, but what we know suggests they may be less far-reaching than claimed.

Voluntary pricing deals reduce uncertainty for major drugmakers. Drug pricing pressure won't affect every pharmaceutical company equally. Strong pipelines remain big pharma's greatest competitive ...